Evidence map›Paper›PMID 42026324›Full record

ArticleThe AAPS journal2026

Quantitative Investigation of ATP Switch Concept of STA551 Through Combined In Vivo Tissue Distribution Studies and Physiologically Based Pharmacokinetic Modeling.

Takayuki Nemoto, Haruka Kuroi, Meiri Shida-Kawazoe, Tatsuhiko Tachibana

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Takayuki NemotoPharmaceutical Science Department, Chugai Pharmaceutical Co., Ltd., Chugai Life Science Park Yokohama, 216 Totsuka-Cho, Totsuka-Ku, Yokohama City, Kanagawa, 244-8602, Japan. nemototky@chugai-pharm.co.jp.ORCID 0009-0008-7440-3925
Haruka KuroiDiscovery Biologics Department, Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, Japan.ORCID 0009-0002-4298-2164
Meiri Shida-KawazoeSpecialty Lifecycle Management Department, Chugai Pharmaceutical Co., Ltd., Chuo-Ku, Tokyo, Japan.ORCID 0009-0007-9659-3486
Tatsuhiko TachibanaPharmaceutical Science Department, Chugai Pharmaceutical Co., Ltd., Chugai Life Science Park Yokohama, 216 Totsuka-Cho, Totsuka-Ku, Yokohama City, Kanagawa, 244-8602, Japan.ORCID 0000-0001-8339-3986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STA551 is an anti-human CD137 (hCD137) switch antibody with adenosine triphosphate (ATP)-dependent antigen binding, developed to achieve potent anti-tumor effects and superior safety. Based on several reports, unlike in normal tissues, high concentrations of ATP are considered to exist in the interstitial space of tumors, thus STA551 is expected to exhibit tumor-selective antigen (hCD137) binding (ATP switch concept). This study aims to quantitatively investigate this ATP switch concept in vivo by combining tissue distribution studies and physiologically based pharmacokinetic (PBPK) modeling. An iodinated conventional anti-hCD137 antibody,

Indexed as

Adenosine TriphosphateAntibodies, MonoclonalModels, BiologicalAnimalsHumansMiceTissue DistributionAdenosine TriphosphateAntibodies, Monoclonaladenosine triphosphate (ATP)antibody tissue distributionCD137physiologically based pharmacokinetic (PBPK) modelingswitch concept

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.